Lonza Earnings Call: Growth Accelerates, Margins Advance

Lonza ((LZAGY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lonza Earnings Call Signals Strong Momentum Despite Select Headwinds

Lonza’s latest earnings call painted a broadly upbeat picture, with management emphasizing strong operational execution, faster-than-expected margin expansion, and sharply improved cash generation in FY2025. While pockets of weakness in Specialized Modalities and currency headwinds were acknowledged, executives struck a confident tone on the company’s ability to outgrow its markets, leverage the Vacaville acquisition, and sustain profitable growth into 2026 and beyond.

Robust Revenue Growth Outpaces Upgraded Guidance

Lonza’s contract development and manufacturing (CDMO) business delivered continuing sales of CHF 6.5 billion in FY2025, up CHF 1.0 billion versus 2024 and representing 21.7% growth at constant currency. This performance came in ahead of the company’s already-upgraded guidance range of 20%–21%, underscoring strong demand across key platforms and the success of recent investments. For investors, this level of growth in a relatively mature life sciences CDMO market reinforces Lonza’s positioning as a key beneficiary of biotech and pharma outsourcing trends.

Margin Expansion and Profitability Move Ahead of Plan

Profitability also stepped up meaningfully, with CORE EBITDA margin rising to 31.6%, an improvement of 1.4 percentage points over the prior year and above the guided 30%–31% corridor. Management signaled further upside, stating they now expect margins above 32% in 2026 and to enter the 32%–34% margin band earlier than previously forecast. The combination of strong top-line growth and accelerating margins supports a compelling earnings trajectory and suggests Lonza is gaining operating leverage from scale, mix, and improved efficiency.

Vacaville Acquisition Delivers Early Upside and Clean Integration

The Vacaville site acquisition is already proving accretive, contributing roughly CHF 0.6 billion of sales in 2025, ahead of the CHF 0.5 billion initially forecast. Management confirmed that post-merger integration was completed by mid-2025, and the first FDA inspection under Lonza’s ownership produced only minor findings that were quickly resolved. This de-risks a major component of the company’s growth plan and validates Lonza’s ability to integrate large assets while maintaining regulatory and operational standards.

Deep Contracting Pipeline Underpins Multi-Year Visibility

Lonza highlighted a strong contracting year, with commercial contracts signed in 2025 exceeding CHF 10 billion, providing solid multi-year revenue visibility. Vacaville alone has already secured five significant long-term contracts and is involved in additional late-stage negotiations. This robust pipeline supports a more predictable earnings profile and underlines Lonza’s appeal as a strategic manufacturing partner for large and emerging biopharma clients.

High-Performing Platforms Led by Advanced Synthesis and Biologics

Advanced Synthesis (ADS) was a standout performer in 2025, posting roughly 22% organic growth and exceptional profitability, with margins above 40% and reported around 42%. Integrated Biologics also delivered strong growth of about 32%, supported by the Vacaville contribution. These platforms remain the core earnings engine for Lonza, demonstrating that the company’s key technologies and capabilities are well aligned with high-demand areas in pharma and biotech.

CapEx Footprint and Growth Investments Shift Past Peak Phase

Lonza continued to invest heavily to expand its manufacturing footprint, executing 23 large growth CapEx projects with a combined value of CHF 7 billion, focused entirely on Europe and the U.S. About 90% of this program is tied to commercial opportunities. CDMO CapEx spend in 2025 was around CHF 1.3 billion, equating to roughly 19.6% of sales. Management indicated that peak CapEx is now behind the company, with a normalization toward high-teen percentages of sales expected, suggesting a gradual shift from build-out to harvest phase for these investments.

Free Cash Flow Nearly Doubles as Cash Generation Improves

Cash generation made a notable step-change in 2025, with continuing-business free cash flow reaching CHF 545 million, almost double the prior year’s level. While trade working capital increased by CHF 200 million in absolute terms, it improved as a percentage of sales by about 5 points, and inventory coverage decreased by nearly one week. These trends point to better working-capital discipline and a gradual freeing up of cash despite the high growth and expansion underway.

ESG and Governance Targets Achieved Ahead of Schedule

Lonza reported significant progress on environmental, social and governance (ESG) metrics, stating that greenhouse gas emission intensity and waste intensity targets were achieved five years earlier than planned. From January 2026, the company is using renewable electricity across its U.S., European and Chinese sites. Recognition from external bodies, including an EcoVadis Gold rating and listing by Ethisphere among the world’s most ethical companies, reinforces Lonza’s positioning as a sustainability and governance leader, which may support its appeal to long-term and ESG-focused investors.

Shareholder Returns and Disciplined Capital Allocation

Reflecting rising earnings power and cash generation, the board has proposed a 25% dividend increase to CHF 5 per share. Management reiterated a balanced capital allocation framework, prioritizing maintenance and infrastructure investments, a progressive dividend, and disciplined discretionary spending including bolt-on M&A. This signals confidence in the cash flow outlook while maintaining flexibility to pursue targeted growth opportunities.

Strengthened Market Positioning and Long-Term Growth Algorithm

Management reaffirmed a long-term growth model in which Lonza addresses selected markets growing in the low teens, estimated at 10%–13% annually. This is driven by underlying market expansion of 6%–7%, additional outsourcing tailwinds of 1%–2%, active market selection contributing 1%–2%, and a further 2%–3% from what Lonza calls its “Engine” advantage. Executives reiterated their belief that Lonza can sustainably outgrow its served markets, reinforcing the company’s status as a structural growth play within the life sciences sector.

Softness in Specialized Modalities Dampens an Otherwise Strong Year

Not all segments fired on all cylinders. Specialized Modalities, which includes Cell & Gene and microbial offerings, underperformed in 2025, with platform revenue declining by about 3%. Management pointed to specific operational issues and execution challenges that limited growth. While these areas represent important long-term technologies, the near-term softness serves as a reminder that newer modalities carry higher operational complexity and risk.

Operational Setbacks in Cell & Gene Expected to Ease

Within Specialized Modalities, operational problems at a Cell & Gene site weighed on results during 2025. Management said these issues have now been resolved and that they anticipate a better performance in 2026, although they did not quantify the prior-year drag or the expected rebound. Investors will likely watch the segment closely to see if Lonza can translate its technical capabilities in Cell & Gene into consistent, scalable, and profitable growth.

Integrated Biologics Faces Margin Dilution from Mix and New Projects

Despite strong topline momentum, Integrated Biologics saw a slight margin decline of 0.9 percentage points in 2025. The business grew around 32%, aided by Vacaville, but faced unfavorable product mix and dilution from new growth projects ramping up. While this is a typical pattern when large new assets and programs come online, it highlights the execution challenge of balancing rapid capacity expansion with margin stability in a highly technical manufacturing environment.

FX Volatility Weighs on Results and Remains a Risk

Foreign exchange movements, particularly a weaker U.S. dollar early in 2025, knocked about 2.5 percentage points off both revenue and profit growth. Management noted that hedging strategies softened the blow but cannot fully remove FX risk. The company still assumes an FX headwind into 2026, acknowledging that currency volatility remains a key external factor that could skew reported results away from the underlying constant-currency performance.

Working Capital and CapEx Still Elevated but Trending Better

Although working capital ratios improved, Lonza’s growth still requires substantial capital and cash tied up in operations. Trade working capital rose by CHF 200 million, and CapEx remained sizeable at CHF 1.3 billion in 2025, with 23 major growth projects worth CHF 7 billion underway. Management framed these outlays as necessary to support contracted and anticipated demand but acknowledged that CapEx and working capital intensity will remain material even as they normalize from peak levels.

Uncertainty Around CHI Exit Proceeds Clouds Capital Flexibility

The company’s CHI business is now classified as discontinued operations, and the exit process is progressing, but management emphasized that the level and timing of any proceeds remains uncertain. This adds a degree of opacity to longer-term capital allocation, particularly for potential larger-scale M&A or accelerated shareholder returns. Investors may treat any CHI-related inflows as an upside option rather than a base-case funding source.

Guidance: Double-Digit Growth and Further Margin Upside in 2026

Looking ahead to 2026, Lonza guided to constant-currency sales growth of 11%–12% and CORE EBITDA margins “well above” 32%, effectively entering the 32%–34% corridor around two years earlier than previously planned. CapEx is expected to moderate to the high-teens percentage of sales in 2026, in line with a mid- to high-teens range over the medium term, following 19.6% of sales in 2025. Management anticipates continued free cash flow momentum after delivering CHF 545 million in 2025 and factors in an FX headwind of roughly 2% for 2026. They also expect Vacaville to broadly replace Roche volumes through 2028 and rely on the more than CHF 10 billion in 2025 contracting, along with improved working capital metrics, to support their growth and margin ambitions.

In sum, Lonza’s earnings call highlighted a company transitioning from heavy investment into a period of accelerated, profitable growth, underpinned by strong demand, a well-filled contract book, and a successful large-scale acquisition. While operational issues in Specialized Modalities, margin pressure in Integrated Biologics, FX volatility, and ongoing capital needs present risks, management’s upgraded margin trajectory, improved cash generation, and clear strategic framework point to a positive outlook that may appeal to investors seeking exposure to long-term structural growth in biopharmaceutical outsourcing.